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1. Introduction 
Chronic Lymphocytic Leukemia (CLL) is a chronic lymphoproliferative disorder of the B 
lymphocytes. Small lymphocytic lymphoma (SLL) is considered to be the same disease in a 
non-leukemic form. CLL remains as an incurable tumour and clinical features have very 
variable presentation, course, and outcome. The progressive accumulation of monoclonal B 
lymphocytes leads to leukocytosis, lymphadenopathy, hepatosplenomegaly and marrow 
failure, and is sometimes associated with autoimmune manifestations.  
It has been suggested that CLL cells are defective in apoptosis, which leads to the 
accumulation of malignant B cells. Furthermore, patients with proliferation rates greater 
than 0.35% per day have been found to have a more aggressive disease18,19. Proliferation of 
CLL cells is most prominent in proliferative centers that include specific areas in lymph 
nodes and bone marow20,21. Numerous CD4 T cells and dendritic cells are in close contact 
with CLL B cells 22, and micro environmental interactions like BM stromal cells are able to 
extend the survival of CLL upon direct contact21. Thus, the CLL population may originate 
from a clone with few or no V- domain mutations, or from a more mature clone whose V-
domains have undergone the hypermutation process. This creates two separate pools of B 
cells, both of which originate from antigen-stimulated B lymphocytes. Additionally, IGHV 
unmutated CLL B cells expressing polyreactive antibodies whereas most IGHV mutated 
CLL´s did not. However, reversion of the IGHV mutated sequences to germline 
counterparts restored the polyreactivity (Herve et al 2005). Despite these features, the 
biological etiology of the divergent natural histories of IgVH unmutated vs mutated CLL 
and the origin of this type of leukemia/lymphoma remains unknown. For this reason we 
review the immunologic aspects that can help to understand this complex disease based in 
the findings that suggest that both unmutated and mutated subgroups of patients originally 
derive from autoreactive clones.  
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2. Diagnosis  
The diagnosis of CLL requires the presence of at least 5000 B lymphocytes/L in the 
peripheral blood (Hallek, et al 2008). CLL/SLL can be identified by the immunophenotype 
CD5+, CD10–, CD19+, CD20+, dim expression of surface immunoglobulin, CD23+, CD43 
+/–, and cyclin D1– (Matutes, et al 2007). The absence of cyclin D1 is critical in 
distinguishing CLL/SLL from MCL. Bone marrow involvement is characteristically more 
than 30% of the nucleated cells in the aspirate are lymphoid. 
Prognostic Markers and Genomic Aberrations 
A favorable prognosis in CLL/SLL is associated with the presence of a mutated 
immunoglobulin heavy chain variable region, and low CD38 and zeta-chain–associated 
protein kinase 70 protein expression(Damle et al 1999;Kröber et al 2002;Hamblin et al 1999; 
Tobbin et al 2002; Crespo et al 2003). Chromosomal aberrations in CLL include del 6q, del 
11q, del 13q, trisomy 12, and del 17p (Döhner et al 2000). Importantly, specific genomic 
aberrations have been associated with disease characteristics such better survival for 
patients with 12q trisomy and 13q deletion, poor survival and massive lymphadenopathy in 
11q deletion and resistance to therapy in the group of patients with 17p deletion and p53 
abnormalities (Döhrner et al 2000; Döhrner et al 1995; Döhrner et al 1997;Krober et al 2006). 
In addition, two miRNA (miR-15a and miR-16-1) were recently identified to be located in 
the critical region of the 13q14 deletion and their absence in CLL appears to be a major factor 
in preventing apoptosis and progression through the cell cycle (Aqeilan et al 2010; Cimmino 
et al 2005; Callin et al 2004; Mertens et al 2006). 
Pathophysiology and cell of origin/normal counterpart of CLL 
Different from other types of malignancies derived from mature B cells, the pathogenesis of 
B-CLL/SLL is much less understood. Notwithstanding extensive searching it is not known 
whether there is an equivalent normal cell in which the CLL arise. However, several cell 
types have been suggested as giving rise to chronic lymphocytic leukemia included 
memory, transitional, B1 and marginal zone B cells (Chiorazzi and Ferrarini 2011; Griffin et 
al 2011). In addition, it is not certain at what stage in lymphocyte maturation the CLL cell 
arises, since roughly equal numbers seem to come from pre-germinal center B lymphocytes 
(unmutated group) and post-germinal center B lymphocytes (mutated group). However, the 
comparison of CLL gene expression profiles with those of purified normal B cell 
subpopulations indicates that the common CLL gene expression profile is more related to 
memory B cells than to those derived from naïve B cells, CD5+ B cells, or germinal center 
centroblasts and centrocytes (Klein et al 2001; Rosenwald et al 2001, Klein and Dalla-Favera 
2005). Interestingly, unmutated and mutated chronic lymphocytic leukemias derive from 
self reactive B cell precursors despite expressing different antibody reactivity (Herve et al 
2005). This similar expression profile also suggest that the consequences or even the 
mechanism of transformation may be similar, irrespective of IGHV mutations status. This 
too suggests that rather than having a cellular origin or cellular subtype, CLL is originated 
by a coordinated normal immunologic tolerance mechanism to destroy self-reactive B cells 
and to avoid autoimmunity during their process of differentiation. This point of view is 
supported by the fact that some CLL mutated and unmutated cases derive from self-reactive 
B cells (Herve et al 2005) had evidence of multiple, related rearranged heavy and light chain 
immunoglobulin genes (Volkheimer et al 2007; Hadzidimitriou et al 2009, Stamatopoulos et 
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al 1996); some express more than one functional Ig heavy chain (Rassenti et al 1997), some 
had been anergized (Mockridge et al 2007; Muzio et al 2008), edited (Hadzidimitriou et al 
2009, Stamatopoulos et al 1996), switched (Cerutti et al 2002) and/or had progressive 
immunoglobulin gene mutation (Volkheimer et al 2007; Roudier et al 1990; Ruzickova et al 
2002). 
Hypothesis: Autoimmunity as origin of CLL 
The basic hypothesis of the origin of autoimmune disease depends of the emergence of a 
clone or a small number of clones of T and B lymphocytes capable of damaging interaction 
with normal cells of organ or tissue involved. Each clone is initiated from a cell which has 
developed an immune receptor adequately reactive with an accessible self antigen as a 
result of a V/D/J gene recombination in bone marrow (unmutated) or during somatic 
mutations in germinal centers (mutated). Importantly, this newly self-reactive cell 
(“forbidden clone”) is anomalously resistant to inactivation by central and peripheral 
tolerance check points (Burnet 1972). Similar to an autoimmune disease, some 
lymphoproliferative diseases (marginal zone lymphomas and chronic lymphocytic 
leukemia) depends of the emergence of a clone capable of interact with an (auto) antigen 
and with other normal cells and an specific microenvironment to proliferate and survive. In 
a parallel way, newly malignant B cells are anomalously resistant to apoptosis and 
proliferate as result of acquisition of genetic damage during V/D/J gene recombination, 
somatic mutations, class switching and receptor edition/revision. Importantly, with the 
exception of class switching, the other mechanisms to increase the diversity of B cell 
receptors might induce both self-reactivity and/or DNA damage.  
B cell development and autoimmunity  
The current model of the pathogenesis of CLL suggest that stimulation by (self) antigens 
provides a pro-survival and possibly pro-proliferative advantage for CLL (precursor) cells, 
most likely leading initially to oligoclonal and subsequently monoclonal selection of 
malignant cells (Mertens et al 2011) 
In humans, B cells develop from progenitors within the bone marrow (Fig1). The stages of B 
cell ontogeny from pro-B to pre-B to early B to mature B cells are marked by phenotypic 
changes, the most important of which is expression of the BCR for antigen on the cell surface 
at the early B cell stage of development (van Lochem et al 2004; Fuda et al 2009) . During the 
course of ontogenesis, B cells mature in the bone marrow according to the evolution of the 
Ig chain synthesis. Starting with the rearrangement of the V/D/J genes for the heavy chain 
at the pre-B stage, the recombination process continues through the VJ gene rearrangements 
for kappa light chain or for the lambda light chain at the immature stage. Thus, the resulting 
receptor (BCR) comprised of randomly selected heavy and light chains have an 
unpredictable specificity that could include ability to bind “self”. However, there are 
tolerance check points at every stage of B cell activation and maturation (table 1 and 2). This 
tolerance mechanisms in bone marrow include receptor editing, clonal deletion, clonal 
anergy and differentiation to B1 cells (Goodnow et al 2005; Radic et al 1993; Tiegs et al 1993; 
Nemazee et al 2000; Luning Prak et al 2011) Notably, current evidence suggest that anergy, 
receptor edition and differentiation to B1 B cells could be implicated in the generation of 
CLL B cells (Herve et al 2005; Chu et al 2010; Mockridge et al 2007; Hadzidimitriou et al 
2009, Stamatopoulos et al 1996; Ghia et al 2008a; Rassenti & Kipps 1997; Murray et al 2008; 
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Griffin et al 2011 ). Additionally , hematopoietic stem cells sorted from a CLL patient´s bone 
marrow produce CLL like disease when transplanted into immunosuppresed mice 
(Kikushige et al 2011). Importantly, autoreactive B cells may suffer receptor editing and 
anergy in bone marrow. At the same, recent evidence shows that L chain receptor editing 
occurs not only in bone marrow with a pre-B/immature B cell phenotype but also in 
immature/transitional splenic B cells. Nevertheless, editing at the H chain locus appears to 
occur exclusively in bone marrow cells with pro-B phenotype (Nakajima et al 2009).  
Repertoire analyses of antibodies cloned from B cells derived from bone marrow and 
peripheral blood of healthy donors provide evidence for both a central tolerance check point 
in the bone marrow and a second peripheral checkpoint, as evidenced by a decrease in the 
frequency of autoreactive antibodies from 75% in bone marrow to 20% in the circulating 
naïve compartment (Yurasov, et al. 2005). Other tolerance mechanisms and peripheral check 
points include memory development check points (Tsuiji et al 2006) CD5+ expression 
(Morikawa et al 1993; Gary-Gouy et al 2002; Hillion et al 2005; Hippen et al 2000, Gary-Gouy 
et al 2002b, Dallou et al 2008), germinal centre exclusion (Cappione et al 2005; Pugh-Bernard 
et al 2001), receptor edition/revision (Luning Prack et al 2011), antibody feedback (Ravetch 
& Bolland 2001), anti-idiotypic network (Jerne 1974; Jerne 1984; Forni et al 1980) and all 
contribute to maintain tolerance and avoid autoimmune diseases.  
The contribution of this mechanism in the development of CLL remain unknown, however, 
Ghia et al describe that CLL expressing IGHV3-21/IGVL3-21 most likely were derived from 
B cells that had experienced somatic mutation and germinal center maturation in an 
apparent antigen driven immune response previous to undergoing Ig receptor editing and 
after germinal-center leukemogenic selection (Ghia et al 2008b). This suggest that peripheral 
tolerance mechanism also contribute to the shape of self reactive CLL B cells generated and 
selected after somatic hypermutation. Other mechanisms as germinal centre exclusion, 
defects in antibody feedback and anti-idiotypic network in lymphoproliferative disorders 
remain unsolved, however some conjectures about their role have been proposed (García-
Muñoz 2009a; García-Muñoz et al 2009b).  
The fact that unmutated and mutated chronic lymphocytic leukemias derive from self 
reactive B cell precursors despite expressing different antibody reactivity (Herve et al 2005) 
suggest that this B cells escape from tolerance mechanisms. Even more Chiorazzi and 
Ferrarini suggest that CLL derives from competent B lymphocytes selected for clonal 
expansion and eventual transformation by multiple encounters and responses to 
(auto)antigen(s) (Chiorazzi and Ferrarini 2003). This two characteristics of CLL B cells guide 
us to think that CLL is the product of the selective pressure of tolerance check points in an 
auto-reactive B cell.  
Development of Unmutated CLL B cells 
Tumors displaying unmutated V genes have a shorter median survival, in one study of 99 
months vs 293 months in the mutated cases (Hamblin et al 1999). Here, a cut-off of >98% 
homology to donor germline gene has been used to define unmutated tumor V genes to 
allow for a low degree of polymorphic allelic variation. There is an association between 
unfavorable cytogenetic aberrations (del 17p and del 11q) and unmutated CLL, although 
13q- is more frequent in mutated CLL. However, there are discrepancies with many cases 
having some high-risk and other low-risk molecular features and more than 50% of IgVH 
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unmutated cases have no unfavorable cytogenetics (Krober et al 2006). Prominently 
unmutated CLL B cells are self reactive or polyreactive (Herve et al 2005) and seem that they 
are resistant to several tolerance mechanism. 
Are unmutated CLL B cells invulnerable to anergy? 
Low BCR signaling induced by weak reactivity to self antigens induce B cells to enter a 
tolerized but alive state referred to as anergy (Gauld et al 2006; Getahun et al 2009) . In most 
cases, anergic B cells are characterized by chronic low level BCR signaling and exhibit 
reduced surface IgM levels but can express high levels of IgD (Getahun et al 2009; Goodnow 
et al 1998; Dolmetsh et al 1997). Interestingly, anergy depends on the degree of BCR 
occupancy and require constant transduction of a BCR signal (Goodnow et al 1989; Benshop 
et al 2001;Gauld et al 2005). Although it is clear that stimulation through the BCR occurred 
during the natural history of all types of CLL, it is quite peculiar that unmutated CLL cells 
retain the capacity to transmit signals through the BCR via surface IgM (Lanham et al 2003). 
The low expression of the BCR is the hallmark of CLL cells and anergic B cells, and appears 
to contribute towards producing poorer responses to BCR stimulation. Despite low levels of 
surface expressed immunoglobulin, signalling through the B cell receptor is possible. ZAP-
70 expression has shown to augment signalling via IgM ligation in CLL cells as measured by 
phosphorylation of downstream mediators such as Syk, BLNK and PLC and calcium influx 
(Chen et al 2005) This increased signalling might lead to enhanced proliferation or survival 
of the leukemic cell (Bernal et al 2001). Significantly, a number of studies have shown a 
strong association between ZAP-70 expression and unmutated IGHV genes. This findings 
could imply that if an immature self-reactive B cell recognize an auto-antigen and also 
express ZAP-70 survival and activating signals prevail over anergy. In this case a self 
reactive CLL B cell selected by a self-antigen during B cell development in bone marrow 
might mature despite they undergo an anergy process and likely to progress to transitional 
and mature B cell. 
Unmutated CLL cases are more frequently CD38 (66-77%) and ZAP-70 (93%) positive, 
exhibit IgM+ and IgD+ surface immunoglobulin, express higher amounts of BCR and 
response better to stimulation compared with mutated CLL´s (Wiestner et al 2003, Hamblin 
et al 2002; Thumberg et al 2001; Döhner et al 2000; Mockridge et al 2007; Guarini et al 2008). 
This characteristics suggest that this unmutated CLL B cells where resistant to anergy and 
progress to mature autoreactive naive B cells.  
Receptor editing be unsuccessful to avoid self-reactivity and might induce polyreactive 
BCR in unmutated CLL B cells 
Immature B cells expressing self-reactive IgM antibodies may undergo repeated rounds of 
light chain rearrangement to lessen the self specificity of the antibody, a process termed 
receptor editing (Nemazee et al 2000; Luning Prak et al 2011). Evidence of receptor editing 
in CLL is provided by the fact that a number of CLL´s have multiple light chain 
rearrangements  (Hadzidimitriou et al 2009). B cell receptor of CLL B cells react with 
recurrent self antigens in vitro including IgG, thyroglobulin, DNA, actin, cardiolipin and 
others as well as microbial antigens and epitopes exposed on cell surface as a result of 
apoptosis and also could be stimulated by stroma-derived antigens (Sthoeger et al 1989; 
Dighiero et al 1991; Chiorazzi et al 2005; Lanemo Myhrinder et al 2008). Sustained or 
repetitive BCR signaling promotes survival in CLL cells (Petlickovsky et al 2005; Bernal et al 
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2001). Notably, unmutated CLL B cells are self reactive or polyreactive (Herve et al 2005). 
Interestingly, 79.3% of unmutated CLL antibodies are polyreactive (Herve et al 2005), and 
reactivity with a particular form of apoptotic cells is a common feature of this subset (Chu et 
al 2010). Even more, recently Rozcova et al revealed that Toll like receptor 9 (TLR-9) agonists 
are a potent stimulus from CLL B cells and induce proliferation, expression of CD38 and 
secretion of cytokines (Rozcova et al 2010). Outstandingly, TLR-9 recognition of self-
molecules (nucleic acids in apoptotic cells) of the host, which are not easily distinguishable 
from those of no-self (infectious organisms) has the potential to provoke autoimmune 
diseases. Intriguingly, the unmutated CLL subset expresses antibodies with long heavy and 
light chain CDR3 (Herve 2005) and some cases of unmutated CLL with 100% of IGHV 
identity have multiple light chain rearrangements (Hadzidimitriou et al TS25 2009), 
associated with receptor edition. This suggest that receptor editing mechanisms could be not 
working well in this subset, even more is possible that increase polyreactivity (Luning Prak 
et al 2011; Binder et al 2010) and promote survival of self-reactive (Sandel et al 1999) CLL B 
cells. Consequently, BCRs that react with diverse epitopes may be more prone to sustained 
signaling. As a result, some unmutated CLL B cells expressing multireactive BCR have a 
more aggressive course than CLLs expressing less reactive BCRs (Binder et al 2010). 
Are unmutated CLL B cells insensitive to CD5 action? 
Induction of CD5 by autoantigen might be a mechanism by which the production of 
autoantibodies is avoided and also maintains tolerance in anergic B cells (Berland et al 2002; 
Hippen et al 2000 ). Recently, a very interesting observation was made that many CLL 
leukemia antibodies recognize non-muscle myosin heavy chain IIA exposed apoptotic cells 
(MEACs) and that natural antibodies from human serum also react with MEACs. In this 
study 15 of 16 MEAC-reactive CLL mAbs carried unmutated IGVH genes (Chu et al 2010). 
Several mechanisms are involved in the tolerance associated with expression of CD5. 
Likewise, CD5 expression prevents B lymphocytes from uncontrolled self reactivity 
increasing the BCR signalling threshold51, and is associated with reexpresion of RAG, 
receptor edition/revision, and lack of responsiveness to BAFF in some cells outside bone 
marrow and germinal centres (Lee et al 2009; Hippen et al 2000, Hillion et al 2005). Along 
this line, the fact that anergic autoreactive B cells may express CD5+ and that 
immunoglobulin secreted by unmutated B-CLL cells is often autoreactive and react with a 
variety of autoantigens (including Fc portion of IgG, DNA, histones, cardiolipin, 
cytoskeletal proteins and insulin) support the notion that unmutated self-reactive B CLL 
cells are under check to avoid pathogenic autoimmunity (Broker et al 1988; Caligaris-Cappio 
et al 1996; Morbach et al 2006). We speculate that the expression of ZAP-70 and CD38 could 
encourage the stimulation of unmutated CLL B cells and overcome the inhibition induced 
by CD5. In addition, CD5 does not inhibit properly the BCR mediating signalling in 
leukemic B cells and in some cases provide viability signals or/and promote CLL B cell 
survival (Perez-Chacon et al 2007; Perez-Chacon 2007b; Gary-Gouy et al 2007; Gary-Gouy et 
al 2002; Gary-Gouy et al 2002).  
Are unmutated CLL B cells transformed human B1 cells? 
Similarities between normal human B1 cells and malignant chronic lymphocytic leukemia 
(CLL) cells, include that both are CD20+CD27+CD43+CD70-; most normal B1 cells express 
CD5, as do malignant CLL cells; and, both express relatively nonmutated IGHV. In addition, 
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normal human B1 cells are ZAP-70+ like unmutated CLL cells. As a final point, in respect to 
pathophysiology, Griffin et al propose that the chronically activated phenotype of normal 
B1 cells may predispose to malignant transformation (Griffin et al 2011). 
Are unmutated CLL naïve self-reactive B cells efficiently excluded by germinal centres? 
In order to prevent autoimmunity, censoring mechanisms, including anergy and 
sequestration into the marginal zone, ultimately forbid the participation of mature 
autoreactive B cells in productive germinal centres reactions, thereby precluding their 
expansion into the long-lived IgG memory and plasma cell compartments. Importantly, 
most self reactive and polyreactive IgG antibodies originate from non self-reactive B cells 
that acquired reactivity by somatic hypermutation (Tiller et al 2007). Significantly, somatic 
hypermutation does not appear to occur uniformly among CLL IGHV genes(Chiorazzi et al 
2005; Fais et al 1998; Tobin et al 2002; Ghia et al 2005) and might suggest the effect of 
germinal centre exclusion and tolerance mechanisms to maintain the self-reactive BCR in a 
germ line state and avoid the participation of unmutated CLL cases in germinal centres 
reactions. 
Development of Mutated CLL B cells 
Fifty percent of CLL patients have undergone somatic hypermutation in IGHV, and these 
patients have a more indolent clinical course and longer survival than those without somatic 
hipermutation (Hamblin et al 1999; Damle et al 1999). The majority of cases of mutated CLL 
fail to signal via IgM in vitro (Lanham et al 2003; Chen et al 2002). Interestingly, CLL B cells 
that express only IgD+ are linked to mutated IGHV genes, negative or low CD38 expression, 
and 50% of mutated CLL cases unable to signal via IgM were able to signal via IgD 
(Stevenson et al 2004). Muzio et al, showed that CLL B cells (typically IGH-mutated cases) 
that do not respond to BCR ligation show activation cellular pathways that suggest anergy 
(Muzio et al 2008). Essentially, mutated CLL cases derive from B cells with self-reactive 
receptors that were anergized, edited or regulated to avoid autoimmunity. This is supported 
by the fact that when mutated non autoreactive immunoglobulin sequences of mutated CLL 
cases were reverted to their germline counterparts, they encoded polyreactive and 
autoreactive antibodies (Herve 2005). Despite somatic hypermutation had been proposed as 
a mechanism to change original BCR self reactivity (germ line) towards some non-self BCR 
(Murray et al 2008), this is an eccentric mode to loss self reactivity because, self reactive 
naive B cells are efficiently excluded from germinal centres (Tsuji et al 2006; Cappione A 3rd 
et al 2005; Pugh-Bernard et al 2001) and if this check point is bypassed B cells progress to 
plasmatic cells that produce auto-antibodies. Still, a significant fraction of self-reactive BCR 
fail to be edited or trigger deletion in primary lymphoid tissues, either because the self-
antigen are bound with only low avidity or because they are not sufficiently abundant in 
primary lymphoid organs. For receptors with intermediate avidity for self antigens, the risk 
they pose for autoimmunity may not overshadow their potential use in fighting infection. B 
cells with receptors that fall into this zone undergo a conditional type of clonal deletion that 
is extrinsically regulated through competition with B cells bearing less self reactive BCR 
(Cyster et al 1994; Lanemo Myhrinder et al 2008). This also can explain that unmutated CLL 
cases and mutated CLL cases express different antibody repertoires and different VH genes 
(Fais et al 1988; Johnson et al 1997). Current data support that CLL cells are in active (auto) 
antigen driven receptor editing, presumably by keeping away from autoreactivity 
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associated with preferential autoimmune linked IGHV gene utilization in CLL patients like 
IGHV3-21, IGHV4-34, IGKV1-17 (Foreman et al 2007; Hadzidimitruiou et al 2009) and also 
IGHV5-51 and IGHV1-69 in unmutated IgVH genes (Chapal et al 2000; Vanura et al 2008). 
Interestingly, highly polyreactive antibodies are expressed frequently by unmutated CLL, 
but only rarely by mutated cases, supporting the view that the receptor editing mechanism 
is significantly active to try to elude autoimmunity in CLL.  
In mutated CLL cases quite a lot of cellular strategies are used to regulate self-reactive 
receptors at different points during B cell differentiation.  
 
 
 
1. The receptor is edited to one that is less self reactive by V(D)J recombination 
(Hadzidimitriou et al 2009; Rassenti et al 1997 Ghia et al 2008b; Kalinina et al 2011). 
2. Regulation by BCR downregulation and anergy (Muzio et al 2008). 
3. Induction of inhibitory receptors as CD5 by self-reactive BCR (Hippen et al 2000; 
Morikawa et al 1993; Dallou et al 2008; Hillion et al 2005). 
 
Table 1. BCR tolerance mechanisms in central lymphoid organs (bone marrow) include 
receptor edition, anergy and induction of inhibitory receptors as CD5. 
Regulation of self reactive receptor in follicles 
Each of the checkpoints described above deal with self-reactive receptor generated by 
V(D)J recombination in the primary lymphoid organs; however, self-reactive BCRs are 
also generated in a second wave of receptor-gene-diversification through somatic 
hypermutation in germinal centre follicles of peripheral lymphoid tissues (Shiono et al 
2003; Radic et al 1994; Ray et al 1996). Despite somatic hypermutation could produce 
modifications in BCR to ablate self-reactivity (Murray et al 2008) also might produce new 
self-reactive BCR. In addition somatic hypermutation poses a particular severe threat of 
autoimmunity for the reason that increase the affinity of antibodies for self-antigens, the 
follicular pathway of B cell differentiation generates long lived plasma and memory cells 
and numerous apoptotic cells be present in germinal centres with self components that are 
trapped and displayed as immune complexes on follicular dendritic cells. For these 
reasons the immune system contain a number of mechanisms to elude the maturation of 
self-reactive B cells that encourage an autoimmune disease. Self-reactivity of mutated CLL 
cases may derive from immature self-reactive B cells that suffer somatic hypermutation or 
by non-self reactive B cells that acquire self-reactive BCR during somatic hypermutation 
in germinal centres. In humans two types of memory B cells have been described: IgM+ 
memory B cells and class-switched memory B cells (Agematsu et al 1997; Klein et al 1998; 
Tangye et al 1998). Transition from naive B cells into circulating IgM+ memory B cells is 
accompanied by efficient counter selection against self reactive naive B cells before the 
onset of somatic hypermutation and that self reactive IgM+ memory B cells present in the 
circulation of healthy humans gain self-reactivity as a result of somatic hypermutation 
(Tsuji et al 2006). 
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The increase in self-reactivity during transition between mature naive and IgG+ memory 
B cells might be due to selective advantage for pre-existing self-reactive cells, or selection 
for cells with self reactive antibodies produced by somatic hypermutation. (Tiller et al 
2007) This mechanisms could contribute to generate the IgG+ CLL cases (Ghiotto F, et al 
2004).  
 
1. Germinal centre exclusion (Tsuji et al 2006; Cappione A 3rd et al 2005; Pugh-Bernard et al 
2001).  
2. The receptor is modified to one that is less self reactive by BCR hypermutation (Murray 
et al 2008, Tiller et al 2007). 
3. Receptor edition/revision (Hadzidimitriou et al 2009; Kalinina et al 2011; Rochas et al 
2007) 
4. CD5 expression (Hillion et al 2005). 
6. Absence of T cell help (Shokat et al 1995) 
7. Competition for follicular niches (Cyster et al 1994) 
Table 2. Tolerance mechanisms in peripheral lymphoid organs. 
Tolerance induced by absence of T-cell help: 
A substantial portion of the activated B cells migrate to germinal centers where they 
undergo the process of somatic hypermutation. These B cells first remove the BCR from 
their surface, then undergo several rounds of division, and finally re-express mutated 
immunoglobulin receptors. The cells then undergo a negative selection process similar to 
that of transitional B cells. The antigen is provided from antigen-antibody complexes on 
follicular dendritic cells. Survival requires the receptor to be of high enough affinity to out-
compete the already circulating antibody and allow B cell uptake and processing of antigen 
For display peptides to primed helper T cells, which have also moved into the germinal 
centers (Kearneay et al 1994). If the B cell receives T cell-help it survives and is stimulated to 
undergo another round of expansion and differentiation. If T cell help is not received, the B 
cell can become anergized or die by apoptosis (Shokat, et al 1995).  
We suggest that in CLL with mutated Ig genes, the proliferating B cells is likely to have 
traversed a germinal center and acquire “de novo self-reactivity” originated in the process of 
somatic hypermutation mechanism or by receptor editon revision. After this “de novo 
autoreactivity” a normal CD5- B cell can theoretically be transformed into a “de novo 
autoreactive memory B cell” that express CD5+ (increase the threshold for BCR activation), 
suffer receptor revision (change light chains to evade autoimmunity), down regulate surface 
Ig (to avoid activation), and remain under check by germinal center exclusion (to diminish 
the chance to progress in the maturation and become plasma cells that produce 
autoantibodies). Finally, all this tolerance mechanism converts this B CD5- B cell into an 
“anergic-edited-CD5+CD27+ memory B cell” excluded from germinal centres. These “de 
novo autoreactive” memory B cells could retain a process of “self-renewal”, a specificity that 
changes (receptor editing-revision) and/or that can not be activated because this “new 
malignant cell” is an “anergic cell” excluded from germinal centres. This speculation could 
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explain why mutated IGVH CLL susbsets (“anergic cells”) have an indolent course related 
to the absence of BCR signalling activation.  
IGVH gene usage in CLL is highly selective, and often associated with autoantibody 
reactivity (Oscier et al 1987). The fact that almost 30 % of CLL patients share BCRs with 
restricted, quasi-identical immunoglobulins sequences should aid the understanding of the 
functional interplay between CLL cells and the microenvironment. On the one hand, 
unmutated IGVH CLL subsets recognizes apoptotic cells in bone marrow and spleen and 
express a functionally competent BCR, as shown by the fact that most of it can be stimulated 
following Ig ligation in vitro. On the other hand, CLL mutated that has acquired “de novo” 
autoreactivity induced by somatic hypermutation recognizes apoptotic cells in germinal 
centres; however they become anergic and are unresponsive throughout BCR stimulation. In 
a CLL mutated subset the “memory-anergic” B cell returns to bone marrow in the same way 
that normal memory B cells.  
Other immunologic alterations that theoretically might predispose the lost of CLL clone 
control: Impaired immunologic synapses 
CD4 and CD8 T cells of patients with CLL show impaired immunological synapse formation 
with antigen presenting cells (APC)(Ramsay et al 2008). This dysfunction is in part induced 
by the CLL B cells. This impaired immunological synapse within T cells and APC could 
contribute to the failure to mount an effective immune response in patients with CLL. 
Moreover, it may also add other immunological abnormalities like hipogammaglobulinemia 
(impaired T cell – B cell interactions), autoimmunity (impaired regulatory T cell control), 
and second tumours (diminished immunosurveillance mediate by NK and CD8 T cells). 
Interestingly, lenalidomide, an immunomodulatory drug, could repair this synapses with an 
enhancement of immune cell function. This effect is clinically observed during treatment of 
CLL patients with this agent because lenalidomide probably induces a strong activation of 
the immune system complicated by swelling of involved lymph nodes and fever named 
tumour flare reaction (Chanan-Khan et al 2006; Aue et al 2009)  
Antibody mediated immunoregulation:  
The antigen-antibody complexes are also likely to be responsible for the phenomenon 
known as original antigenic sin, in which memory B cells, generated during a prior exposure 
to a cross-reacting antigen, present or down-regulate the response to these unique new 
determinants on the antigen70. Memory B cells seem to have an advantage for rapid 
activation and this produces antibodies that feed back to inhibit the priming of naïve B cells 
possessing receptors that are specific to unique determinants of the second immunogen. 
This feedback mechanism is most likely mediated through antigen-antibody complexes that 
interact with FcRIIb on the naïve B cells and inhibit signal transduction through their IgM 
receptors (Ravetch et al 2001). In patients with hipogammaglobulinemia this feedback 
mechanism is impaired and might contribute to expansion of autoreactive B cells (García-
Muñoz 2009b) , and in patients with CLL it may add an additional risk to uncontrolled 
proliferation of CLL clones. 
Anti-idiotypic B cell regulation: In 1974 Jerne proposed that antibody production could be 
regulated by other antibodies that recognized unique idiotypic determinants in the V 
regions of the first antibody. He postulated that an increase in the production of the first 
antibody could negatively regulate the production of anti-idiotypic antibodies, and vice 
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versa. Because of the interconnected pathways in such a network, perturbation of one 
segment would be dampened by the presence of others segments and thus the original 
steady state would be buffered (Jerne 1984; Jerne 1970; Forni et al 1980).  
Patients with CLL have an increased proportion of autoimmune haemolytic anemia (AIHA) 
and idiopatic autoimmune thrombocytopenia (ITP) and infections. It is probable that the 
idiotypic network is disrupted in CLL patients and that this could lead to an increased risk 
of autoimmunity on one hand and immunodeficiency on the other. Treatment with 
intravenous immunoglobulins (IVIg) could in theory restore idiotypic network and antigen-
antibody-complexes feedback in CLL B cells. Remarkably, patients with AIHA treated with 
IVIg experiment a reduction of the size of lymph nodes and spleen (Diehl et al 1998). This 
suggests that immune-complexes feedback and idiotypic network could contribute 
indirectly in the control of CLL. 
MYD88 Mutation  
Interestingly, mutations in MYD88 and KLHL6 genes have been reported recently in 
patients with mutated CLL patients (Puente et al 2011). Significantly, similar to CLL patients, 
patients with MYD88-deficiency do not secrete autoantibodies (Isnardi et al 2008). We 
speculate that if mutations in MYD88 gene were acquired during germinal center reaction, is 
possible that self-reactive B cells cannot progress to plasmatic cells but retain some features 
or memory B cells. Even more, TLR-9 acts via MYD88 and might induce proliferation of CLL 
B cells. However, mutations in MYD88 might disturb the function of this TLR-9 and 
contribute to the biology and better prognosis of mutated CLL cases.  
IGHV gene usage in CLL is highly selective, and often associated with autoantibody 
reactivity. The fact that almost 30 % of CLL patients share BCRs with restricted, quasi-
identical immunoglobulins sequences should aid to the understanding of the functional 
interplay between CLL cells and the microenvironment. On the one hand, unmutated IGHV 
CLL subsets recognizes apoptotic cells in bone marrow and spleen and express a 
functionally competent BCR, as shown by the fact that most of it can be stimulated 
following Ig ligation in vitro. On the other hand, CLL mutated that has acquired “de novo” 
autoreactivity (¿mutations in MYD88?) induced by somatic hypermutation recognizes 
apoptotic cells in germinal centres; however they become anergic and are unresponsive 
throughout BCR stimulation. In a CLL mutated subset the “memory-anergic” B cell returns 
to bone marrow in the same way that normal memory B cells.  
3. Conclusion 
Chronic lymphocytic leukemia can be separated into cases that harbour somatic mutation in 
their IGVH genes, or cases without somatic mutations. IGVH gene usage in CLL is highly 
selective, and often associated with autoantibody reactivity. Despite the fact that the cell 
surface markers and gene expression of CLL cells suggest that both subsets originate from a 
precursor cell of the same developmental stage, these findings could be only the result of 
several immunologic mechanisms that try to destroy or avoid the persistence of self-reactive 
CLL B cells. CLL is characterized by multiple immune deficiencies and autoimmune 
phenomena associated with persistent tolerance mechanism trying to control self-reactive 
CLL B cells growth. 
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B-cell development occurs initially in the bone marrow and subsequently in lymphoid organs. In bone 
marrow, hematopoietic progenitor cells (HSC) differentiate into the earliest identifiable cell type 
committed to the B-cell lineage, the pro-B cell. The pro-B cell undergoes a rearrangement of its 
immunoglobulin (Ig) heavy chain genes and is called a pre-B cell. Subsequent rearrangement of the 
light chain enables the cell to express surface IgM and the cell becomes an immature transitional B 
lymphocyte. These cells leave the bone marrow and are called naïve B cells. They are arrested in the G0 
phase of the cell cycle. These naïve B cells enter the lymphoid tissue, where they are exposed to antigen-
presenting cells, become activated and differentiate into plasma cells or memory B cells. Through 
activation by an antigen, B cells differentiate into centroblasts, resulting in Ig isotype switching and 
somatic mutations in the variable region of the Ig with the generation of high-affinity antibodies. 
Centroblasts then progress to the centrocyte stage and re-express surface Ig. The centrocytes with high-
affinity antibodies differentiate into either memory B cells or plasmablasts, which subsequently move to 
the bone marrow and terminally differentiate into plasma cells. 
 
 
 
Fig. 1. Normal B cell development. 
www.intechopen.com
 
Is Chronic Lymphocytic Leukemia a Mistake of Tolerance Mechanisms? 
 
73 
 
 
 
 
 
 
 
Unmutate CLL B-cell development occurs initially in the bone marrow and subsequently in lymphoid 
organs. In bone marrow, hematopoietic progenitor cells (HSC) differentiate into the pro-B cell that use 
IGHV genes related with autoimmunity. The pro-B cell undergoes a rearrangement of its 
immunoglobulin (Ig) heavy chain genes and is called a pre-B cell. Subsequent rearrangement of the 
light chain enables the cell to express surface self reactive BCR that fail to be corrected by several 
rounds of receptor edition. This self-reactive B cells acquire Zap-70 or other alterations that induce 
increased BCR activation. This is the way in which this self-reactive CLL B cells pass up tolerance 
mechanisms as anergy and inhibition exerted by CD5. These cells leave the bone marrow as unmutated 
polyreactive CLL B cells. These unmutated polyreactive CLL B cells enter in the lymphoid tissue, where 
they are exposed to antigen-presenting cells and self-antigens, however, they cannot be converted into 
plasma cells or memory B cells with mutations because they are efficiently excluded by germinal 
centers.  
 
 
Fig. 2. Hypothesis about generation of unmutated B cells (García-Muñoz et al. Ann Hematol. 
Accepted). 
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Mutated CLL B-cell development occurs initially in the bone marrow and subsequently in lymphoid 
organs. In bone marrow, hematopoietic progenitor cells (HSC) differentiate into the pro-B cell that use 
IGHV genes related with autoimmunity. The pro-B cell undergoes a rearrangement of its 
immunoglobulin (Ig) heavy chain genes and is called a pre-B cell. Subsequent rearrangement of the 
light chain enables the cell to express surface self reactive BCR that fail to be corrected by several 
rounds of receptor edition. This self-reactive B cells enter in germinal centres and undergo somatic 
hypermutation in order to negate their autoreactivity. This is the way in which this self-reactive CLL B 
cells pass up tolerance mechanisms as germinal centre exclusion, however, fortunately they suffer some 
mutations to reverse their self reactivity and avoid autoimmune diseases as SLE. These cells leave the 
germinal center as mutated CLL B cells memory like cells.  
 
 
 
Fig. 3. “Impaired Germinal Centre exclusion model for development of mutated CLL cases 
wiht VH4-34. 
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Mutated CLL B-cell development occurs initially in the bone marrow and subsequently in lymphoid 
organs. In bone marrow, hematopoietic progenitor cells (HSC) differentiate into the pro-B cell that use 
IGHV genes related with autoimmunity. The pro-B cell undergoes a rearrangement of its 
immunoglobulin (Ig) heavy chain genes and is called a pre-B cell. Subsequent rearrangement of the 
light chain enables the cell to express surface self reactive BCR that succeed to be corrected by several 
rounds of receptor edition. This ex-self-reactive B cells acquire CD5 or other alterations that induce 
lesser BCR activation. This is the way in which this ex-self-reactive CLL B cells suffer tolerance 
mechanisms as receptor edition, anergy and inhibition exerted by CD5. These cells leave the bone 
marrow as unmutated normal naïve B cells. These naïve ex-self reactive B cells enter in germinal centres 
and suffer somatic hypermutation (SHM) and acquire a new self-reactive BCR, however, again 
tolerance mechanisms as receptor edition/revision and CD5 expression make this cells in an anergic 
memory ex-self-reactive B cells. Importantly, reversion of the IGHV mutated sequences to germline 
counterparts restored the polyreactivity and self-reactivity. 
Fig. 4. Mutated CLL B cells generated by somatic hypermutation (García Muñoz et al. Ann 
Hematol. Accepted).  
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